Ipamorelin, sermorelin, tesamorelin, CJC-1295, BPC-157 and GHK-Cu have different regulatory histories, evidence and risks. They are not interchangeable, and none should be described as an FDA-approved anti-aging therapy.
This is educational information, not a treatment menu. CJC-1295, BPC-157, ipamorelin and injectable GHK-Cu are not FDA-approved medicines. Tesamorelin has approved prescription products for a specific medical condition, not general weight loss or anti-aging. Historical sermorelin approval does not confer approval on compounded preparations. This page does not offer, sell, prescribe or provide access to these products.
Ipamorelin
Ipamorelin is a growth hormone secretagogue, a substance that stimulates growth hormone release. It is not an FDA-approved medicine. Claims that it reverses aging or reliably improves recovery, sleep, muscle or body composition are not established by its mechanism of action.
FDA identifies potential immune-reaction and impurity risks for compounded ipamorelin acetate and insufficient safety information for certain injectable routes. Serious adverse events, including deaths, were reported in an intravenous study for gastric motility. These reports do not establish causation or the safety of another route. Combining ipamorelin with another peptide does not establish safety or approval.
Sermorelin: historical approval is not compounded-drug approval
Sermorelin affects growth hormone signaling. The former Geref products had specific pediatric growth hormone deficiency and diagnostic uses. FDA determined that their discontinuation was not for safety or effectiveness reasons. That history is not approval of compounded sermorelin or an anti-aging indication.
Compounded sermorelin is not FDA-approved and has not undergone FDA premarket review for safety, effectiveness and quality. Growth hormone signaling alone does not establish improved energy, muscle, recovery or longevity in otherwise healthy adults. Eligibility and lawful compounding require assessment of the exact preparation and circumstances.
Tesamorelin: a specific approved indication
Egrifta WR is an FDA-approved tesamorelin prescription product for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label does not indicate it for weight-loss management. This is not approval for anti-aging, longevity, athletic performance or general body-fat reduction. Approval of a branded product does not approve compounded tesamorelin.
Important risks include elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity reactions. The label lists contraindications including active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis. Long-term cardiovascular safety has not been established. This is not a complete safety summary; the full prescribing information and an individual assessment are essential.
CJC-1295
CJC-1295 is a research peptide discussed in relation to growth hormone signaling. It is not an FDA-approved medicine. A biological mechanism is not proof that a product improves recovery, builds muscle or reverses aging.
FDA identifies limited clinical data, potential immune reactions and reported serious adverse events, including increased heart rate and systemic vasodilatory reactions. This information does not establish an appropriate treatment, route or dose.
BPC-157
BPC-157 is an investigational peptide. Laboratory and animal findings do not establish that it heals injuries or treats digestive conditions in people. It is not an FDA-approved medicine.
FDA identifies concerns about immune reactions, impurities and limited safety information. An advisory committee discussion or recommendation does not itself authorize compounding or constitute FDA drug approval.
GHK-Cu: injectable and topical products differ
GHK-Cu is a copper-containing peptide. An injectable preparation and a topical skin-care product are different products and cannot be treated as interchangeable. Injectable GHK-Cu is not an FDA-approved medicine.
FDA flags potential immune-reaction and impurity risks for injectable GHK-Cu, with limited human safety data. The presence of a copper peptide in a cosmetic does not establish that injections are safe or effective. A specific topical product requires its own assessment of ingredients, intended use and claims; this page does not endorse one.
Understanding approval and evidence
Drug approval applies to an exact product, formulation and indication. It is not approval for every use of its ingredient, for a peptide blend, or for compounded versions. Compounded medicines are not FDA-approved.
Human evidence, manufacturing quality, route and the proposed use all matter. Research-use labeling, pharmacy licensure and preliminary advisory recommendations do not substitute for product approval or establish that a treatment is appropriate. This guide does not recommend an anti-aging peptide regimen or provide dosing instructions.
Questions before considering a treatment
Ask an appropriately licensed clinician to identify the exact medicine and formulation, explain its regulatory status, and compare the evidence, risks and alternatives for the diagnosed condition. Do not use online information as a dosing guide or purchase research chemicals for self-treatment.
Persistent fatigue, injury or changes in strength deserve an assessment. Established approaches such as rehabilitation when indicated, adequate nutrition, sleep and appropriate activity may form part of an individual care plan.